Archive of Oncology
kako citirati ovaj članak
podeli ovaj članak


  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:3
  • preuzimanja u poslednjih 30 dana:1


članak: 1 od 4  
Back povratak na rezultate
2019, vol. 25, br. 2, str. 13-18
Assessment of pathological response to neoadjuvant chemotherapy in patients with breast carcinoma using Sataloff system
(naslov ne postoji na srpskom)
aUttar Pradesh University of Medical Sciences, Department of Pathology, Saifai, Etawah, India
bUttar Pradesh University of Medical Sciences, Department of Radiotherapy and Oncology, Saifai, Etawah, India
cUttar Pradesh University of Medical Sciences, Department of Surgery, Saifai, Etawah, India

Ključne reči: Pathology; Lymph; Carcinoma; Breast
(ne postoji na srpskom)
Background: Neoadjuvant chemotherapy is frequently administered to patients with breast carcinoma. Response to chemotherapeutic regime can be assessed clinically as well as by pathological examination of the breast tissue. It is essential to accurately categorize the patients with residual disease according to the standard guidelines for pathological evaluation of breast specimens after neoadjuvant chemotherapy. The present study was undertaken to assess the histomorphological changes in mastectomy specimens and axillary lymphatic nodes of patients receiving neoadjuvant chemotherapy, grade the pathological response using Sataloff system and to compare the clinical and pathological response after neoadjuvant chemotherapy. Methods: Present prospective study included a total of 31 patients with locally advanced breast carcinoma, diagnosed with infiltrating ductal carcinoma, not otherwise specified on biopsy specimen and subsequently treated with 2 to 6 cycles of neoadjuvant chemotherapy. Pathological response to neoadjuvant chemotherapy was assessed in breast and axillary lymphatic nodes according to Sataloff criteria. Results: Clinical response observed was complete (cCR) in four cases (12.9%), partial response (cPR) in 24 cases (77.4%), and no response (cNR) in three cases (9.7%). Based on tumor response, breast and lymph nodes were graded as pathological complete response (pCR), pathological partial response (pPR), and pathological no response (pNR) in five (16.1%), 18 (58.1%) and eight (25.8%) cases respectively using Sataloff criteria. Ductal carcinoma in situ and lymphovascular invasion were seen in 11 (35.4%) and 16 cases (51.6%), respectively. Conclusion: The pathological assessment of tumor response remains the gold standard, as neither the clinical nor the radiological responses are sensitive predictors of tumor response after treatment. However pathological examination is quite challenging and demands sufficient experience along with detailed clinical and radiological data of pre-and postoperative neoadjuvant chemotherapy for precise response evaluation.
Bear, H.D., Anderson, S., Brown, A., Smith, R., Mamounas, E.P., Fisher, B., Margolese, R., Theoret, H., Soran, A., Wickerham, D., Wolmark, N. (2003) The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. Journal of Clinical Oncology, 21(22): 4165-4174
Chin, S.N., Green, C.M.A., Gordon-Strachan, G.M., Wharfe, G.H.F. (2014) Locally Advanced Breast Cancer in Jamaica: Prevalence, Disease Characteristics and Response to Preoperative Therapy. Asian Pacific Journal of Cancer Prevention, 15(7): 3323-3326
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J.P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., Swain, S.M., Prowell, T., Loibl, S., Wickerham, L.D., Bogaerts, J. (2014) Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet, 384(9938): 164-172
Devita, V.T., Lawrence, T.S., Rosenberg, S.A. (2009) DeVita, Hellman, and Rosenberg's Cancer: Principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins, 8th ed. 337-386
Earl, H., Provenzano, E., Abraham, J., Dunn, J., Vallier, A., Gounaris, I., Hiller, L. (2015) Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes: What does it all mean?. BMC Medicine, 13(1)
Fayanju, O.M., Nwaogu, I., Jeffe, D.B., Margenthaler, J.A. (2015) Pathological complete response in breast cancer patients following neoadjuvant chemotherapy at a Comprehensive Cancer Center: The natural history of an elusive prognosticator. Molecular and Clinical Oncology, 3(4): 775-780
Frierson, H.F., Fechner, R.E. (1994) Histologic Grade of Locally Advanced Infiltrating Ductal Carcinoma After Treatment with Induction Chemotherapy. American Journal of Clinical Pathology, 102(2): 154-157
Ju, N.R., Jeffe, D.B., Keune, J., Aft, R. (2013) Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 137(1): 195-201
Lambein, K., van de Vijver, K., Faverly, D., Colpaert, C. (2011) Belgian guidelines for laboratory handling and pathology reporting of breast carcinoma after neoadjuvan therapy. Belg J Med Oncol, 5:144-53
Mamounas, E.P., Anderson, S.J., Dignam, J.J., Bear, H.D., Julian, T.B., Geyer, C.E., Taghian, A., Wickerham, L.D., Wolmark, N. (2012) Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results from Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. Journal of Clinical Oncology, 30(32): 3960-3966
Mauri, D., Pavlidis, N., Ioannidis, J.P.A. (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. JNCI: Journal of the National Cancer Institute, 97(11): 858-859
Park, C.K., Jung, W., Koo, J.S. (2016) Pathologic Evaluation of Breast Cancer after Neoadjuvant Therapy. Journal of Pathology and Translational Medicine, 50(3): 173-180
Penault-Llorca, F., Abrial, C., Raoelfils, I., Cayre, A., Mouret-Reynier, M., Leheurteur, M., Chollet, P. (2008) Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer. Human Pathology, 39(8): 1221-1228
Provenzano, E., Bossuyt, V., Viale, G., Cameron, D., Badve, S., Denkert, C., Macgrogan, G., Penault-Llorca, F., Boughey, J., Curigliano, G., Dixon, M.J., Esserman, L., Fastner, G., Kuehn, T. (2015) Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: Recommendations from an international working group. Modern Pathology, 28(9): 1185-1201
Rajan, R., Poniecka, A., Smith, T.L., Yang, Y., Frye, D., Pusztai, L., Fiterman, D.J., Gal-Gombos, E., Whitman, G., Rouzier, R., Green, M., Kuerer, H., Buzdar, A.U., Hortobagyi, G.N., Symmans, F.W. (2004) Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer, 100(7): 1365-1373
Rousseau, C., Devillers, A., Sagan, C., Ferrer, L., Bridji, B., Campion, L., Ricaud, M., Bourbouloux, E., Doutriaux, I., Clouet, M., Berton-Rigaud, D., Bouriel, C., Delecroix, V., Garin, E. (2006) Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography. Journal of Clinical Oncology, 24(34): 5366-5372
Sahoo, S., Lester, S.C. (2009) Pathology of breast carcinomas after neoadjuvant chemotherapy: An overview with recommendations on specimen processing and reporting. Arch Pathol Lab Med, 133: 633-675
Sataloff, D.M., Mason, B.A., Prestipino, A.J., Seinige, U.L., Lieber, C.P., Baloch, Z. (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome. J Am Coll, 180: 297-306
Sethi, D., Sen, R., Parshad, S., Sen, J., Khetarpal, S., Garg, M. (2013) Histopathologic changes following neoadjuvant chemotherapy in locally advanced breast cancer. Indian Journal of Cancer, 50(1): 58-58
Sharkey, F.E., Addington, S.L., Fowler, L.J., Page, C.P., Cruz, A.B. (1996) Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma. Mod Pathol, 9: 893-900
Shintia, C., Endang, H., Diani, K. (2016) Assessment of pathological response to Neoadjuvant chemotherapy in locally advanced breast cancer using the Miller-Payne system and TUNEL. Malays J Pathol, 38: 25-32
Smith, I.C., Heys, S.D., Hutcheon, A.W., Miller, I.D., Payne, S., Gilbert, F.J., Ah-See, A.K., Eremin, O., Walker, L.G., Sarkar, T.K., Eggleton, P.S., Ogston, K.N. (2002) Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response with Docetaxel. Journal of Clinical Oncology, 20(6): 1456-1466
Tanioka, M., Shimizu, C., Yonemori, K., Yoshimura, K., Tamura, K., Kouno, T., Ando, M., Katsumata, N., Tsuda, H., Kinoshita, T., Fujiwara, Y. (2010) Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy. British Journal of Cancer, 103(3): 297-302
Teshome, M., Hunt, K.K. (2014) Neoadjuvant Therapy in the Treatment of Breast Cancer. Surgical Oncology Clinics of North America, 23(3): 505-523
Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A. (2015) Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 65(2): 87-108
Vasudevan, D., Jayalakshmy, P.S., Kumar, S., Mathew, S. (2015) Assessment of Pathological Response of Breast Carcinoma in Modified Radical Mastectomy Specimens after Neoadjuvant Chemotherapy. International Journal of Breast Cancer, 2015: 1-8
von Minckwitz, G., Untch, M., Blohmer, J., Costa, S.D., Eidtmann, H., Fasching, P.A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., Jackisch, C., Kaufmann, M., Konecny, G.E., Denkert, C. (2012) Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. Journal of Clinical Oncology, 30(15): 1796-1804
Vujaskovic, Z., Kim, D.W., Jones, E., Lan, L., McCall, L., Dewhirst, M.W., Craciunescu, O., Stauffer, P., Liotcheva, V., Betof, A., Blackwell, K. (2010) A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. International Journal of Hyperthermia, 26(5): 514-521
Wang-Lopez, Q., Chalabi, N., Abrial, C., Radosevic-Robin, N., Durando, X., Mouret-Reynier, M., Benmammar, K., Kullab, S., Bahadoor, M., Chollet, P., Penault-Llorca, F., Nabholtz, J. (2015) Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?. Critical Reviews in Oncology/Hematology, 95(1): 88-104

O članku

jezik rada: engleski
vrsta rada: članak
DOI: 10.2298/AOO190128001A
objavljen u SCIndeksu: 29.07.2019.
metod recenzije: jednostruko anoniman
Creative Commons License 4.0

Povezani članci

Nema povezanih članaka